about
Extensive recombination among human immunodeficiency virus type 1 quasispecies makes an important contribution to viral diversity in individual patients.Contribution of Recombination to the Evolution of Human Immunodeficiency Viruses Expressing Resistance to Antiretroviral TreatmentIn vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIVInhibitory effects of archetypical nucleic acid ligands on the interactions of HIV-1 nucleocapsid protein with elements of Psi-RNA.A look inside HIV resistance through retroviral protease interaction mapsImpact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected childrA decade of viral mutations and associated drug resistance in a population of HIV-1+ Puerto Ricans: 2002-2011Prediction of potency of protease inhibitors using free energy simulations with polarizable quantum mechanics-based ligand charges and a hybrid water model.Prevalence of drug-resistance mutations and non-subtype B strains among HIV-infected infants from New York State.Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutationsThe K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutationsImpact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimenSequence and structure based models of HIV-1 protease and reverse transcriptase drug resistance.Genotypic predictors of human immunodeficiency virus type 1 drug resistance.Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies.Protease inhibitor associated mutations compromise the efficacy of therapy in human immunodeficiency virus-1 (HIV-1) infected pediatric patients: a cross-sectional study.Review of tipranavir in the treatment of drug-resistant HIV.Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection.HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance.The relationship between resistance and adherence in drug-naive individuals initiating HAART is specific to individual drug classes.Web resources for HIV type 1 genotypic-resistance test interpretation.Oral complications of HIV disease.Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistanceGenotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir.In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.
P2860
Q22242225-F8A228CD-A4A2-4494-A21B-0803BA4F7623Q22242229-4AD4A6DB-6759-4F25-A11C-2E2E78C2CD10Q24672993-45BE9EA3-885D-4ABA-A817-D080F2F12339Q25255792-6F32387D-B0C2-4DED-8496-EF1E1036F997Q28469157-37975F6D-F141-4275-8A03-58A8A100D9E2Q33267065-7FE83242-7850-4DC2-B760-B7E7DC95738AQ33664179-AA56E827-6E2B-4A63-98BD-75EB34E3EC08Q33814096-37E3147B-3ABD-4D5A-A4C6-AAFEABE70DA0Q34079002-9664F362-6493-40B4-87F5-87D850CDD7D7Q34331628-EE0AF6CB-87FE-4B3F-89DF-819FE316129AQ34647936-BFF876CF-8171-420D-BA27-13FF00BED089Q34680647-409F5593-ED07-4A0C-9627-041D71CE6F83Q35051539-E0047271-6726-4A87-8F13-BC0E276AF2E0Q35108499-123696F6-1F1E-49A0-9D46-087F1C94B666Q35300021-771B0B1A-79AB-47A2-B812-E9CDD45414BEQ35962627-9DE652A1-1AAC-400D-A86D-5CAFE8BE16F1Q36642990-4A3B01D6-6A21-4A8A-8700-C5DB14757A95Q36673315-AD5D62EC-FBF2-49F4-9A0B-6A0429A53203Q36696351-3663589D-8465-449E-ADD2-22BFF21A8D9DQ36712414-DED99557-0C1C-4220-BE93-17A58513744BQ36899999-0E96AD0A-D5E4-46F4-A63B-DA012FBFBD3BQ37222240-587B8861-2B49-4969-8A46-F266DC02EF3CQ37277757-94496B91-1465-4FA0-AA03-0B494DD4AF80Q39290078-7A049DF5-AD67-48B2-B5A0-5E7D7E6BCDFFQ40902737-C7B07FE9-F7C5-499A-846E-F48506346DE1
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Update of the Drug Resistance Mutations in HIV-1: 2005.
@ast
Update of the Drug Resistance Mutations in HIV-1: 2005.
@en
type
label
Update of the Drug Resistance Mutations in HIV-1: 2005.
@ast
Update of the Drug Resistance Mutations in HIV-1: 2005.
@en
prefLabel
Update of the Drug Resistance Mutations in HIV-1: 2005.
@ast
Update of the Drug Resistance Mutations in HIV-1: 2005.
@en
P2093
P1476
Update of the Drug Resistance Mutations in HIV-1: 2005
@en
P2093
Amalio Telenti
Bonaventura Clotet
Brian Conway
Daniel R Kuritzkes
Deenan Pillay
Douglas Richman
Francoise Brun-Vezinet
Jonathan Schapiro
Victoria A Johnson
P577
2005-03-01T00:00:00Z